Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Structure Therapeutics Inc (GPCR)
Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,881,880
  • Shares Outstanding, K 46,386
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,320 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.65
Trade GPCR with:

Options Overview Details

View History
  • Implied Volatility 77.66% ( +3.81%)
  • Historical Volatility 57.25%
  • IV Percentile 52%
  • IV Rank 9.36%
  • IV High 222.91% on 12/15/23
  • IV Low 62.67% on 02/01/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 12,915
  • Volume Avg (30-Day) 909
  • Put/Call OI Ratio 1.22
  • Today's Open Interest 6,689
  • Open Int (30-Day) 5,504

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.22
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.88 +3.41%
on 02/26/24
50.07 -17.64%
on 02/12/24
-3.83 (-8.50%)
since 02/01/24
3-Month
26.61 +54.98%
on 12/18/23
66.38 -37.87%
on 12/04/23
-18.33 (-30.77%)
since 12/01/23
52-Week
21.12 +95.27%
on 03/15/23
75.02 -45.03%
on 11/01/23
+18.31 (+79.85%)
since 03/01/23

Most Recent Stories

More News
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now

It has genuine struggles ahead, but it has some actual value in hand as well.

PFE : 26.59 (+0.11%)
GPCR : 41.24 (+1.65%)
LLY : 782.12 (+3.77%)
2 Biotech Stocks That Could Soar in December

These two biotechs have important catalysts coming up in December.

BLUE : 1.5650 (+12.59%)
GPCR : 41.24 (+1.65%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 2.20 (+9.45%)
RYTM : 43.71 (+0.67%)
VKTX : 85.22 (+10.60%)
GPCR : 41.24 (+1.65%)
NVO : 124.23 (+3.72%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 2.20 (+9.45%)
RYTM : 43.71 (+0.67%)
VKTX : 85.22 (+10.60%)
GPCR : 41.24 (+1.65%)
NVO : 124.23 (+3.72%)
Why Shares of Structure Therapeutics Are Up Monday

The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug.

NVO : 124.23 (+3.72%)
LLY : 782.12 (+3.77%)
GPCR : 41.24 (+1.65%)
Why Shares of Structure Therapeutics Are Soaring on Friday

The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate.

NVO : 124.23 (+3.72%)
LLY : 782.12 (+3.77%)
GPCR : 41.24 (+1.65%)
Why Shares of Structure Therapeutics Rose Monday

The company's lead diabetes and weight-loss therapy may benefit from a decision by Pfizer.

PFE : 26.59 (+0.11%)
GPCR : 41.24 (+1.65%)
This Biotech Is Developing The Next Ozempic. Should You Buy It?

If it succeeds, it'll still face a battle for market share.

NVO : 124.23 (+3.72%)
GPCR : 41.24 (+1.65%)
Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years

If you can tolerate the risk and have some patience, both stocks could blossom.

NVO : 124.23 (+3.72%)
VKTX : 85.22 (+10.60%)
GPCR : 41.24 (+1.65%)
There's a Lot to Love About Mineralys' Valentine's Day IPO

MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million

MLYS : 15.34 (-0.26%)
AZN : 64.60 (+0.69%)
CINC : 29.06 (-0.48%)
GPCR : 41.24 (+1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 47.25
2nd Resistance Point 45.66
1st Resistance Point 43.11
Last Price 41.24
1st Support Level 38.97
2nd Support Level 37.38
3rd Support Level 34.83

See More

52-Week High 75.02
Fibonacci 61.8% 54.43
Fibonacci 50% 48.07
Fibonacci 38.2% 41.71
Last Price 41.24
52-Week Low 21.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar